Vigil Neuroscience (NASDAQ:VIGL) Price Target Lowered to $17.00 at HC Wainwright

Vigil Neuroscience (NASDAQ:VIGL) had its price target reduced by HC Wainwright from $24.00 to $17.00 in a research report sent to investors on Friday, Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Several other equities analysts have also recently weighed in on VIGL. Wedbush restated an outperform rating and set a $23.00 price target on shares of Vigil Neuroscience in a report on Thursday, July 11th. JMP Securities restated a market outperform rating and set a $23.00 price target on shares of Vigil Neuroscience in a report on Thursday, April 18th.

Vigil Neuroscience Trading Up 5.1 %

Shares of VIGL opened at $3.91 on Friday. The business’s 50 day moving average is $3.87 and its 200 day moving average is $3.37. The company has a market capitalization of $146.94 million, a PE ratio of -1.84 and a beta of 2.00. Vigil Neuroscience has a 12-month low of $2.47 and a 12-month high of $9.24.

Vigil Neuroscience (NASDAQ:VIGL) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.10. Equities research analysts predict that Vigil Neuroscience will post -2.1 earnings per share for the current year.

Hedge Funds Weigh In On Vigil Neuroscience

A hedge fund recently bought a new stake in Vigil Neuroscience stock. Strs Ohio bought a new position in Vigil Neuroscience, Inc. (NASDAQ:VIGL) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 8,200 shares of the company’s stock, valued at approximately $27,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.